热门资讯> 正文
PMV Pharma IPO定价为5000万美元，每股1.21美元
2026-09-01 16:47
- PMV Pharmaceuticals (PMVP) priced an oversubscribed public offering expected to raise about $50.8M in gross proceeds.
- The offering includes 22.055M shares of common stock and pre-funded warrants to purchase up to 19.9M shares, along with warrants to purchase an aggregate of 41.955M shares of common stock.
- The combined offering price is $1.21 per share and accompanying warrant. Pre-funded warrants are priced at $1.20999 each, with an exercise price of $0.00001 per share.
- PMV Pharma is a precision oncology company developing small-molecule therapies targeting p53. The company said TP53 mutations are found in approximately half of all cancers.
- The offering is expected to close on or about September 2.
More on PMV Pharmaceuticals
- Seeking Alpha’s Quant Rating on PMV Pharmaceuticals
- Historical earnings data for PMV Pharmaceuticals
- Financial information for PMV Pharmaceuticals
推荐文章
一周财经日历 | 影响加息大事！9月大小非农数据重磅登场；美光、希音齐放榜！景旺电子、欢创科技等5只新股下周上市
Q4净利或狂飙逾1000%！美光能否交出”炸裂“财报？三大焦点将影响股价走向
休市提醒：中秋假期来临，港股9月25日（周五）正常开市
华盛早报 | 强劲PMI催高加息预期！纳指回调1%；美财政部拟再回购60亿美元长债；SpaceX总裁套现逾5200万美元
美股前瞻 | 特朗普最新调仓曝光！抛售微软，买入英伟达；Meta科技盛会重磅来袭；高盛、德银齐看多：标普500将冲刺8000点
特朗普重新定义AI：美国今后将把人工智能称为“超级智能”
Muse为何让Meta市值暴涨数千亿美元
特朗普将亮相联大：聚焦伊朗 密集会见多国领导人 计划与丹麦签署协议
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
